arrow
M

Mayfong Mayxay

naval medical research center (nmrc)
H指数:60
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Population pharmacokinetics of artemether–lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria

青蒿醚-卢伏氟胺联合阿莫地喹在无并发症的 *Plasmodium falciparum* 疟疾患者中的群体药代动力学

2025-10-060
OAAI
Leptospirosis Prevalence and Risk Factors Among Patients Presenting With Fever to 4 Healthcare Sites in Sub-Saharan Africa and South East Asia: An International Multisite Observational and Nested Case-Control Study

莱姆病流行率及风险因素:来自撒哈拉以南非洲和东南亚4个医疗机构的发热患者国际多中心观察性及巢式病例对照研究

2025-10-010
OAAI
Prevalence and risk factors for murine typhus, scrub typhus and spotted fever group rickettsioses among adolescent and adult patients presenting to Yangon General Hospital, Yangon, Myanmar

缅甸仰光市仰光总医院就诊的青少年和成人患者中,流行性斑疹伤寒、恙虫病和斑点热群立克次体病的患病率及危险因素。

2025-07-170
OA
Evolution and significance of neuronal surface autoantibodies after Japanese encephalitis

日本脑炎后神经元表面自身抗体的演变及意义

2025-06-200
PRE
Pneumococcal density and respiratory co-detection in severe pediatric pneumonia in Laos

肺炎链球菌密度及呼吸道共检测在老挝重症儿童肺炎中的研究

2025-05-210
OA
Genetic surveillance of Plasmodium falciparum populations following treatment policy revisions in the Greater Mekong Subregion

Greater Mekong Subregion中恶性疟原虫种群的遗传监测及其治疗政策修订后的研究

2025-05-200
OA
Landscape and climatic drivers of dengue fever in Lao People's Democratic Republic and Thailand: a retrospective analysis during 2002-2019

老挝人民民主共和国和泰国登革热的景观与气候驱动因素:2002-2019年的回顾性分析

2025-05-150
OA
Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos)
2024-01-015
OAAI